Globeflex Capital L P Raises Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Globeflex Capital L P raised its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 203.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 975,151 shares of the biotechnology company's stock after buying an additional 654,200 shares during the period. Exelixis comprises approximately 2.8% of Globeflex Capital L P's investment portfolio, making the stock its 6th biggest position. Globeflex Capital L P owned approximately 0.34% of Exelixis worth $32,473,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of EXEL. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Exelixis by 18.1% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company's stock worth $63,000 after acquiring an additional 290 shares in the last quarter. Steward Partners Investment Advisory LLC increased its stake in Exelixis by 4.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company's stock worth $235,000 after purchasing an additional 330 shares in the last quarter. Oregon Public Employees Retirement Fund raised its holdings in Exelixis by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company's stock worth $1,937,000 after buying an additional 354 shares during the period. Principal Securities Inc. lifted its stake in Exelixis by 62.8% during the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after buying an additional 373 shares in the last quarter. Finally, V Square Quantitative Management LLC boosted its holdings in shares of Exelixis by 37.3% in the fourth quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company's stock worth $52,000 after buying an additional 425 shares during the period. Institutional investors own 85.27% of the company's stock.

Remove Ads

Exelixis Price Performance

EXEL traded down $0.56 on Tuesday, hitting $36.46. The company had a trading volume of 729,128 shares, compared to its average volume of 2,066,475. The stock has a market cap of $10.20 billion, a price-to-earnings ratio of 20.59, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The company's fifty day moving average price is $35.44 and its 200 day moving average price is $32.60. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $40.02.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, sell-side analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on EXEL shares. UBS Group upped their price target on shares of Exelixis from $30.00 to $34.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. JMP Securities reaffirmed a "market outperform" rating and issued a $41.00 target price on shares of Exelixis in a research report on Thursday, January 23rd. Stifel Nicolaus raised their price objective on Exelixis from $30.00 to $36.00 and gave the stock a "hold" rating in a research report on Wednesday, February 12th. Stephens reaffirmed an "equal weight" rating and set a $29.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. Finally, Brookline Capital Management started coverage on shares of Exelixis in a research report on Monday, December 23rd. They issued a "buy" rating for the company. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Exelixis currently has a consensus rating of "Moderate Buy" and an average target price of $37.59.

Insiders Place Their Bets

In related news, EVP Patrick J. Haley sold 10,000 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $38.80, for a total transaction of $388,000.00. Following the completion of the transaction, the executive vice president now owns 341,028 shares of the company's stock, valued at approximately $13,231,886.40. The trade was a 2.85 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bob Oliver sold 18,647 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total value of $694,600.75. Following the completion of the sale, the director now directly owns 33,514 shares in the company, valued at $1,248,396.50. This trade represents a 35.75 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock valued at $5,177,234 in the last quarter. Insiders own 2.85% of the company's stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.